MARKET

GRAY

GRAY

Graybug Vision, Inc.
NASDAQ
0.6900
-0.0149
-2.11%
Opening 14:37 02/03 EST
OPEN
0.6701
PREV CLOSE
0.7049
HIGH
0.6900
LOW
0.6701
VOLUME
5.56K
TURNOVER
1.89K
52 WEEK HIGH
1.580
52 WEEK LOW
0.4501
MARKET CAP
14.88M
P/E (TTM)
-0.4007
1D
5D
1M
3M
1Y
5Y
BRIEF-Graybug Vision Receives Notice Of Delisting From Nasdaq
Reuters · 12/28/2022 21:06
Why American Eagle Outfitters Shares Climbed Over 18%; Here Are 78 Biggest Movers From Yesterday
Benzinga · 11/23/2022 10:25
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 11/22/2022 17:31
Graybug Vision Agrees To Merge With Inflammatory Disease-Focused Biopharma
Benzinga · 11/22/2022 14:50
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 11/22/2022 13:08
Graybug Vision, CalciMedica Agree to Merge in All-Stock Deal
Graybug Vision, CalciMedica Agree to Merge in All-Stock Deal
MT Newswires · 11/22/2022 05:57
Reported Late Monday, Graybug And CalciMedica Enter Into Definitive Merger Agreement To Combine The Companies In An All-Stock Transaction; The Combined Company Will Focus On Further Developing CalciMedica's Lead Product Candidate Auxora
Benzinga · 11/22/2022 05:37
BRIEF-Graybug And Calcimedica Enter Into Definitive Merger Agreement
Reuters · 11/21/2022 23:55
More
About GRAY
Graybug Vision, Inc. is a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases. The Company's products include GB-102 and GB-401. GB-102 is a lead product designed to provide pan-vascular endothelial growth factor (VEGF) inhibition for six months or longer while minimizing fluctuations in retinal thickness in between treatments. GB-102 is a once-every-six month intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD). The Company is also evaluating and developing GB-102 for the treatment of diabetic retinopathy (DR). GB-401, is an intravitreally administered, proprietary implant formulation containing a prodrug of a beta-adrenergic receptor inhibitor designed to provide a controlled release of the active drug to maintain reduced intraocular pressure (IOP) for six months or longer after a single injection for the treatment of primary open-angle glaucoma.

Webull offers kinds of Graybug Vision Inc stock information, including NASDAQ:GRAY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GRAY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GRAY stock methods without spending real money on the virtual paper trading platform.